Lung cancer is the leading cause of cancer deaths in the world today.1
The standard of care for lung cancer has been a combination of surgery, chemotherapy, and radiation. But each of these therapies is fraught with significant collateral damage.
Precision oncology seeks to minimize the adverse side effects associated with surgery, chemotherapy, and radiation by offering a more targeted approach.
Listen to why we believe Precision Oncology is a compelling investment theme as Eventide CIO Finny Kuruvilla, MD, PhD, explains how treating cancers like lung cancer at the molecular level yields fewer side effects and better outcomes.
This communication is provided for informational purposes only and expresses views of Eventide Asset Management, LLC ("Eventide"), an investment adviser. There is no guarantee that any investment strategy will achieve its objectives, generate profits, or avoid losses. Eventide's values-based approach to investing may not produce desired results and could result in underperformance compared with other investments. Any reference to Eventide’s Business 360 approach is provided for illustrative purposes only and indicates a general framework of guiding principles that inform Eventide’s overall research process. Investing involves risk including the possible loss of principal. Past performance does not guarantee future results.
Before investing or sending money, an investor should carefully review investment objectives, risks, charges and expenses as provided in prospectuses and other information available at www.eventidefunds.com or by calling 1-877-771-EVEN (3836). Eventide Asset Management, LLC serves as investment adviser to the Eventide mutual funds distributed through Northern Lights Distributors, LLC (“NLD”), member FINRA/SIPC. NLD and Eventide are not affiliated entities.